The MDR1/ABCB1 gene, a high-impact risk factor for cardiac transplant rejection

Transplantation

Volumn 82, Issue 12, 2006, Pages 1677-1682

  Barnard, James B ^a   Richardson, Steven ^a   Sheldon, Stephen ^b   Fildes, James ^a   Pravica, Vera ^c   Hutchinson, Ian V ^c   Leonard, Colm T ^a   Yonan, Nizar ^a  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^c National Institute of Transplantation Los Angeles   (United States)

Author keywords

Gene polymorphism; Heart transplantation; MDR1 ABCB1; P glycoprotein; Rejection

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID; PREDNISOLONE; TACROLIMUS;

ADULT; CARDIAC GRAFT REJECTION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GENE AMPLIFICATION; GENETIC CORRELATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC RISK; GENOTYPE; GRAFT RECIPIENT; HAPLOTYPE; HEART GRAFT; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; UNSPECIFIED SIDE EFFECT;

ADULT; EXONS; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 33845955117     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000250724.09996.bd     Document Type: Conference Paper

References (28)

1. Tanigawara Y. Role of P-glycoprotein in drug disposition. Ther Drug Monit 2000; 22: 137-140.
2. Terao T, Hisanaga E, Sai Y, et al. Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J Pharm Pharmacol 1996; 48: 1083.
3. Owen A, Chandler B, Bray PG, et al. Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4. J Virol 2004; 78: 12022.
4. Donnenberg VS, Burckart GJ, Griffith BP, Jain AB, Zeevi A, Berg AD. P-glycoprotein (P-gp) is upregulated in peripheral T-cell subsets from solid organ transplant recipients. J Clin Pharmacol 2001; 41: 1271.
5. Kim RB, Leake BF, Choo EF, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001; 70: 189.
6. Hauser IA, Schaeffeler E, Gauer S, et al. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol 2005; 16: 1501.
7. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein: from genomics to mechanism. Oncogene 2003; 22: 7468.
8. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000; 97: 3473.
9. Woodahl EL, Ho RJ. The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function. Curr Drug Metab 2004; 5: 11.
10. Illmer T, Schuler US, Thiede C, et al. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 2002; 62: 4955.
11. Jamroziak K, Mlynarski W, Balcerczak E, et al. Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol 2004; 72: 314.
12. Kafka A, Sauer G, Jaeger C, et al. Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int J Oncol 2003; 22: 1117.
13. Siegsmund M, Brinkmann U, Schaffeler E, et al. Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol 2002; 13: 1847.
14. Tsuchiya N, Satoh S, Tada H, et al. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 2004; 78: 1182.
15. Haufroid V, Mourad M, Van Kerckhove V, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004; 14: 147.
16. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. Jama 1989; 261: 3561.
17. Sheldon S, Yonan NA, Aziz TN, et al. The influence of histocompatibility on graft rejection and graft survival within a single center population of heart transplant recipients. Transplantation 1999; 68: 515.
18. Kobashigawa JA, Kirklin JK, Naftel DC, et al. Pretransplantation risk factors for acute rejection after heart transplantation: a multiinstitutional study. The Transplant Cardiologists Research Database Group. J Heart Lung Transplant 1993; 12: 355.
19. Renlund DG, Gilbert EM, O'Connell JB, et al. Age-associated decline in cardiac allograft rejection. Am J Med 1987; 83: 391.
20. Densem CG, Ray M, Hutchinson IV, et al. Interleukin-6 polymorphism: a genetic risk factor for cardiac transplant related coronary vasculopathy? J Heart Lung Transplant 2005; 24: 559.
21. Schneider S, Roessli D, Excoffier L. Arlequin Genetics and Biometry Laboratory. Geneva: University of Geneva, 2000.
22. Cascorbi I, Gerloff T, Johne A, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001; 69: 169.
23. Bonhomme-Faivre L, Devocelle A, Saliba F, et al. MDR-1 C3435T polymorphism influences cyclosporine a dose requirement in liver-transplant recipients. Transplantation 2004; 78: 21.
24. Zheng H, Webber S, Zeevi A, et al. The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients. Hum Immunol 2002; 63: 765.
25. von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M, Armstrong VW. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 2001; 47: 1048.
26. Georges E, Sharom FJ, Ling V. Multidrug resistance and chemosensitization: therapeutic implications for cancer chemotherapy. Adv Pharmacol 1990; 21: 185.
27. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981; 41: 1967.
28. Pouliot JF, L'Heureux F, Liu Z, et al. Reversal of P-glycoprotein- associated multidrug resistance by ivermectin. Biochem Pharmacol 1997; 53: 17.